Form 4: Castle Biosciences COO Kristen Oelschlager Sells Shares Under 10b5-1 Plan

Kristen Oelschlager, Chief Operating Officer of Castle Biosciences, sold shares of common stock on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Kristen Oelschlager, the Chief Operating Officer of Castle Biosciences, sold shares of the company's common stock on August 1, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on March 15, 2024.
• A total of 8,764 shares were sold at a weighted-average price of $22.715, with individual trades ranging from $22.14 to $23.13.
• An additional 4,225 shares were sold at a weighted-average price of $23.77, with individual trades ranging from $23.23 to $24.09.
• Following these transactions, Oelschlager directly owns 132,836 shares of Castle Biosciences common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by an insider. It doesn't inherently convey positive or negative sentiment.

Industry Context

This is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale may have a minor negative impact on shareholder sentiment, but is unlikely to have a significant impact due to the pre-planned nature of the sales.

Key Dates